Palvella Therapeutics Inc. Common Stock (PVLA)

About PVLA

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

29

Website

palvellatx.com

Fundamentals

1-day range

$154.35$160.33

Market cap

$2.02B

P/E (trailing)

—

P/E (forward)

-20.82

EPS (trailing)

$-4.86

Dividend yield

—

Beta

—

Avg. volume

252.7K

Forecasts

15 analyst ratings

Palvella Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• PVLA

  Palvella Therapeutics Inc. Common Stock

  $149.97

  ▼ 0.24%
  Market cap $2.02BP/E —
  $46.08$161.38
• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.01BP/E —
  $7.48$18.57
• ZBIO

  Zenas BioPharma Inc. Common Stock

  $31.29

  ▼ 4.08%
  Market cap $1.97BP/E —
  $13.5$44.6
• MLYS

  Mineralys Therapeutics Inc. Common Stock

  $25.59

  ▼ 1.61%
  Market cap $2.13BP/E —
  $14.94$47.65
• NUVB

  Nuvation Bio Inc. Class A Common Stock

  $6.67

  ▼ 4.65%
  Market cap $2.14BP/E —
  $2.87$9.75
• AUPH

  Aurinia Pharmaceuticals Inc Ordinary Shares

  $16.3

  ▼ 1.09%
  Market cap $1.89BP/E 6.39
  $10.34$19.25
• NBTX

  Nanobiotix S.A. American Depositary Shares

  $41.28

  ▼ 8.59%
  Market cap $1.88BP/E —
  $7.02$47.66

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

13.53M

Total value held

$1.63B

Institutional holders

176